Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alireza Atri

Neurological Surgery Boston, MA Medical Doctor

NPI 1326038506 CMS profile 195469

15 Parkman St, Wac 830, Boston, MA 02114

Open in the dashboard

General payments

$502,543

268 records reported · program years 2019–2025

Research payments

$70,575

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,206,362 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Alireza Atri of Boston, MA is reported in the CMS Open Payments database as having received $502,543 across 268 general payments and $70,575 in research payments paid to them. Separately, studies naming them as principal investigator received $1,206,362 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $23,000 19
2024 General $51,862 49
2023 General $136,801 63
2023 Research $56,648 1
2022 General $53,350 30
2022 Research $3,927 2
2021 General $89,074 20
2021 Research $6,500 1
2020 General $79,717 27
2020 Research $3,500 1
2019 General $68,740 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alireza Atri
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Alireza Atri were reported at $23,000. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Alireza Atri Neurological Surgery median Middle half National median
2019 $68,740 $582 $138–$3,006 $163
2020 $79,717 $294 $76–$2,174 $114
2021 $89,074 $387 $105–$2,432 $132
2022 $53,350 $542 $139–$2,989 $149
2023 $136,801 $534 $145–$2,697 $160
2024 $51,862 $574 $155–$3,046 $164
2025 $23,000 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. H. Lundbeck A S $93,135 17 payments
  2. Eisai Inc. $92,121 67 payments
  3. Biogen, Inc. $85,675 18 payments
  4. Novo Nordisk Inc $52,182 27 payments
  5. Novo Nordisk AS $51,996 15 payments
  6. ACADIA Pharmaceuticals Inc $31,568 19 payments
  7. Grifols Shared Services North America, Inc. $26,036 14 payments
  8. Genentech USA, Inc. $18,538 13 payments
  9. Roche Products Limited $13,073 5 payments
  10. Lundbeck LLC $11,911 13 payments
  11. Other $26,309 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $333,869 71 payments
  2. Honoraria $88,650 9 payments
  3. Travel and Lodging $52,382 71 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,070 12 payments
  5. Food and Beverage $7,572 105 payments
Products named General payments · program years 2019–2025
  1. REXULTI Psychiatry $57,884 23 payments
  2. Leqembi $40,704 31 payments
  3. Flebogamma DIF $25,592 16 payments
  4. NUPLAZID Parkinsons Disease Psychosis $24,928 17 payments
  5. Albutein $20,960 9 payments
  6. ADUHELM $12,632 6 payments
  7. Non-Covered Product $7,281 7 payments
  8. DISEASE EDUCATION $4,240 1 payment
  9. REXULTI Psychiatry $2,473 24 payments
  10. NUPLAZID Parkinsons Disease Psychosis $2,400 1 payment
  11. Other $111 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Genentech, Inc. $56,648 1 payment
  2. Novo Nordisk AS $13,927 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Neurology: 833

Drug cost

$249

Median for Neurology: $202,670

Branded share of claims

0%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Donepezil Hcl Generic 12 $249

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$17,992

Medicare's payments for the services billed

Medicare patients

22

Average age 73

Services billed

379

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Alzheimer's or dementia 75%
High blood pressure 64%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $11,836
$11,836 — —
Leqembi
  • Eisai Inc. $5,189
$5,189 — —
AMYVID
  • Lilly USA, LLC $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

273 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record